David Thompson

David Thompson is a Co-Founder, General Partner and serves as Chief Financial Officer of 415C. David has over 35 years of experience in corporate management, audit and finance, the last 25 years in the medical technology sector. He has invested in over 20 medical technology companies and co-founded and managed several European medical device distribution companies, including CoRRect Medical GmbH (acquired by Uniphar PLC in 2021), Regis Medical GmbH (merged with CoRRect Medical GmbH), Ovum Ventures GmbH (sold to Medtronic 2009), and Cardiologic GmbH (sold to Boston Scientific in 2002). Following Boston Scientific’s acquisition of Cardiologic GmbH, he served as a Finance Controller for Boston Scientific in Germany, Austria and Switzerland.

Prior to joining Cardiologic GmbH as Co-General Manager in 1996, David was the CFO of Chiron Adatomed GmbH, a German subsidiary of Chiron Corporation (NASDAQ: CHIR). Prior to that, he worked in Ernst & Young’s Munich office, advising on corporate M&A transactions. David holds a degree in Accountancy from the University of Birmingham, UK and is a member of the Institute of Chartered Accountants in England & Wales (ACA, ICAEW).